Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
Firas S. Ahmed, Laurent Dercle, Gregory Goldmacher, Hao Yang, Dana E. Connors, Ying Tang, Sanja Karovic, Binsheng Zhao, Richard D. Carvajal, Caroline Robert, Michael L. Maitland, Geoffrey R. Oxnard, Lawrence H. Schwartz
Topics & Concepts
MedicinePembrolizumabResponse Evaluation Criteria in Solid TumorsClinical trialRadiologyInternal medicineOncologyNuclear medicineImmunotherapyPhases of clinical researchCancerCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersOcular Oncology and Treatments